華安醫學股份有限公司 Approved
最後更新時間 2025/07/18 , 07:18 AM
最後更新時間 2025/07/18 , 07:18 AM
負責人
Chen,Han-Min
統一編號
53726093
成立日期
2012/08/28
資本額
NT$1,500,000,000
實收資本額
NT$886,580,000
股票代號
6657
電話
02-82213701
地址
6-3F, No. 21, Ln. 583, Rueiguang Rd., Neihu Dist., Taipei City, 114, Taiwan
董監事
姓名 職稱 持有股份 代表法人
Chen,Han-Min Chairman 6.50%
Huang,Jin-Hua Vice Chairman 0.93%
Cai,Chong-Rong Director 0.00%
Weng,Wei-Jun Director 0.09%
Wu,Shou-Shan Independent Director 0.00%
Wu,Yu-Ren Independent Director 0.00%
Ding,Ke-Hua Independent Director 0.00%
營業項目
  • Wholesale of Other Food(454999)
  • Wholesale of Other Machinery and Equipment(464999)
  • Wholesale of Cosmetics(457299)
  • 公司歷程
  • Change Capital to 1,500,000,000
    2024/06/12
  • Change Company Name to ENERGENESIS BIOMEDICAL CO., LTD.
    2018/12/03
  • Change Capital to 1,000,000,000
    2018/12/03
  • Change Company Name to KANG YUHUI
    2018/06/26
  • Change Capital to 500,000,000
    2015/04/27
  • Change Capital to 33,000,000
    2014/11/04
  • 員工人數
    下載完整報告查看完整數據
    財務報表
    項目 2025 2024 2023
    Operating income 1,213 7,749 7,158
    Operating cost 233 2,059 1,931
    Profit (loss) of initial recognition of biological asset and agricultural products - - -
    Profit (loss) on changes in fair value less costs to sell of biological asset for current period - - -
    Operating gross profit (loss) 980 5,690 5,227
    Unrealized profit (loss) on sales of goods - - -
    Realized profit (loss) on sales of goods - - -
    Operating gross profit (loss), net 980 5,690 5,227
    Operating expenses 101,776 260,859 267,064
    Other gain (loss), net - - -
    Operating profit (loss) -100,796 -255,169 -261,837
    Non-operating income and expenses 3,823 24,089 1,455
    Net profit (loss) before tax -96,973 -231,080 -260,382
    Income tax expense (benefits) - - -
    Net profit (loss) of ongoing business for the current period -96,973 -231,080 -260,382
    Profit (loss) of closed units - - -
    Profit (loss) of non-jointly controlled equity before merger - - -
    Net profit (loss) for the current period -96,973 -231,080 -260,382
    Other comprehensive profit (loss), net 52 94 -
    Comprehensive net profit and loss of non-jointly controlled equity before merger - - -
    Total comprehensive profit and loss for the current period -96,921 -230,986 -260,382
    Net profit (loss) attributable to owners of parent company -96,973 -231,080 -
    Net profit (loss) form equity attributable to former owner of business combination under common control - - -
    Net profit (loss) attributable to non-controlling interests - - -
    Comprehensive profit (loss) attributable to owners of parent company -96,921 -230,986 -
    Comprehensive profit (loss) form equity attributable to former owner of business combination under common control - - -
    Comprehensive profit (loss) attributable to non-controlling interests - - -
    Basic earnings per share (yuan) -1 -3 -3
    項目 2025 2024 2023
    Net cash inflow (outflow) from operating activities -115,887 -180,711 -
    Net cash inflows (outflows) from investing activities -281,426 193,230 -
    Net cash inflow (outflow) from financing activities 430,869 145,285 -
    Effect of Exchange Rate Changes on Cash and Cash Equivalents 52 94 -
    Increase (decrease) in cash and cash equivalents in the current period 33,608 157,898 -
    Beginning balance of cash and cash equivalents 404,506 246,608 -
    Ending balance of cash and cash equivalents 438,114 404,506 -
    項目 2025 2024 2023
    Current asset 1,030,916 687,746 719,444
    Non-current asset 93,217 92,892 109,126
    Total asset 1,124,133 780,638 828,570
    Current liability 37,464 35,832 21,344
    Non-current liability 7,919 5,473 3,243
    Total liability 45,383 41,305 24,587
    share capital 888,509 905,700 760,752
    Equity - secruity token - - -
    capital reserve 518,148 64,619 393,898
    retained earning -328,053 -231,080 -350,667
    Other equity 146 94 -
    Treasury stock - - -
    Total equity attributable to owners of parent company 1,078,750 739,333 -
    Equity attributable to former owner of business combination under common control - - -
    Equity attributable to non-controlling interest before business merger under common control - - -
    Non-controlling interests - - -
    Total Equity 1,078,750 739,333 803,983
    Share capital awaiting retirement (unit: share) - - -
    Issued shares of advance equity (unit: shares) 164,000 2,932,498 38,000
    Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) 0 0 0
    Net asset value per share 12 9 10
    動產抵押
    下載完整報告查看完整數據
    案件類別 債務人名稱 債務人統編 契約啟始日期 契約終止日期 抵押權人名稱 抵押權人統編 擔保債權金額
    選舉收入(政治獻金)
    收入名稱 收入金額
    總收入金額
    選舉支出(政治獻金)
    支出名稱 支出金額
    總支出金額
    標案拒往
    機關名稱 生效日期 截止日期
    進出口資料
    下載完整報告查看完整數據
    年份 月份 總進口實績(美金) 總出口實績(美金)
    商標
  • Orka
  • orkagen設計圖
  • energenesis biomedical
  • Visual Protein
  • LuminolPen
  • ImmunoFast
  • PhosPRO
  • VisPRO
  • 專利
    政府標案
    標案名稱 機關名稱 決標日期 決標金額 是否得標
    裁判書查詢
    勞權違規
    日期 違反法規法條 罰鍰金額
    污染源裁處
    污染類別 裁處時間 裁處機關 裁處金額 違反事實 違反法令 裁處書字號 裁處理由及法令 公司地址
    本頁內所載之資料,所載資料之完整性、即時性和正確性仍應以資料來源單位為準。
    公司一有新動態,我們馬上通知你,追蹤公司讓你不錯過任何更新。